Conn H O, Poynard T
Yale University School of Medicine, West Haven, Connecticut.
J Intern Med. 1994 Dec;236(6):619-32. doi: 10.1111/j.1365-2796.1994.tb00855.x.
This meta-analysis was performed to determine whether corticosteroid therapy induces the development of peptic ulcer and other putative complications of steroid therapy.
A retrospective investigation in which we analysed all the randomized, double-blind, controlled trials (RDBCT) in which steroids had been administered that we were able to identify. The number of episodes of peptic ulcer, dermatological effects, sepsis, diabetes, hypertension, osteoporosis, psychosis and tuberculosis reported in both the placebo and steroid groups were compared.
The international medical literature was analysed for any RDBCT in which any steroid or ACTH had been administered in any dosage for any duration, and any putative complication of steroid therapy was reported.
Of 1857 articles, 93 satisfied our requirements and were analysed by the meta-analytic techniques of Peto, DerSimonian and Laird. A total of 6602 patients were included.
The relative frequencies of each of these eight 'complications' were compared in the placebo and steroid groups using conventional statistics and meta-analysis. The relative frequencies of 'annualized' subgroups of patients who received treatment for 1 to 7 days, 1 week to 1 month, 1 to 3 months and more than 3 months, were similarly analysed.
Nine of 3267 patients in the placebo group (0.3%) and 13 of 3335 patients in the steroid group (0.4%) were reported to develop peptic ulcer (P > 0.05). The dermatological cosmetic effects of steroid therapy were observed more frequently in the steroid group (P < 0.001), as was diabetes (P < 0.001), hypertension (P < 0.01) and psychosis (P < 0.001). Sepsis, osteoporosis and tuberculosis all occurred more frequently in the steroid than in the placebo group, but the differences are not statistically significant.
Peptic ulcer is a rare complication of corticosteroid therapy that should not be considered a contraindication when steroid therapy is indicated.
进行此项荟萃分析以确定皮质类固醇疗法是否会引发消化性溃疡及类固醇疗法的其他假定并发症。
一项回顾性调查,分析我们能够识别的所有使用类固醇的随机、双盲、对照试验(RDBCT)。比较安慰剂组和类固醇组中报告的消化性溃疡发作次数、皮肤效应、败血症、糖尿病、高血压、骨质疏松症、精神病和结核病的情况。
分析国际医学文献中任何使用任何剂量、任何时长的任何类固醇或促肾上腺皮质激素(ACTH)且报告了类固醇疗法任何假定并发症的RDBCT。
在1857篇文章中,93篇符合我们的要求,并采用Peto、DerSimonian和Laird的荟萃分析技术进行分析。共纳入6602例患者。
使用传统统计学方法和荟萃分析比较安慰剂组和类固醇组中这八种“并发症”各自的相对频率。对接受治疗1至7天、1周至1个月、1至3个月以及超过3个月的患者的“年化”亚组的相对频率进行类似分析。
安慰剂组3267例患者中有9例(0.3%)被报告发生消化性溃疡,类固醇组3335例患者中有13例(0.4%)发生消化性溃疡(P>0.05)。类固醇疗法的皮肤美容效应在类固醇组中观察到的频率更高(P<0.001),糖尿病(P<0.001)、高血压(P<0.01)和精神病(P<0.001)也是如此。败血症、骨质疏松症和结核病在类固醇组中的发生频率均高于安慰剂组,但差异无统计学意义。
消化性溃疡是皮质类固醇疗法的一种罕见并发症,在有类固醇疗法指征时不应将其视为禁忌证。